← Evidence library

BIB_198

NICE TA544 — Adjuvant dabrafenib + trametinib for resected BRAF V600 mutation-positive stage III melanoma. 2018. COMBI-AD evidence basis. [Tasks: 19a, 18] Tier: 2 Grade: N/A Retrieved: 2026-05-07

Evidence grade

N/A

Tier

2

Cited by tasks

19a, 18

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_198/findings.md (research corpus). This page is a short context summary — not individualised medical advice.